We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Research interviews
-
1. Advancing ALS genetics through accessible testing
- Dr. Teresa Fecteau
-
2. Integrated multimodal cell atlas of Alzheimer’s disease
- Dr. Michael Hawrylycz
-
5. Transmembrane domains and the regulation of trogocytosis in T cells- Dr. Stefano Barbera
-
6. Pioneering proteomics: insights on advancements in the science of proteins
- Prof. Ruedi Aebersold
-
7. The state of the art in secondary pharmacology
- Dr. Jean-Pierre Valentin
-
8. How liver X receptor regulates intestinal regeneration and tumor growth
- Dr. Srustidhar Das
-
10. Using real-world insights on drug interactions to inform drug development
- Dr. Amita Datta-Mannan
-
11. The role of preregistration and registered reports in improving research transparency and reproducibility
- Dr. Peter Bonde Ernst-Rasmussen
-
12. Decoding aging: how a proteomic clock predicts mortality and disease across populations
- Dr. M. Austin Argentieri
-
13. Role of ETS2 in autoimmune and inflammatory diseases
- Dr. James Lee
-
14. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD
- Prof. Katrin Andreasson
-
15. The safety, toxicology, and regulation of antibody-drug conjugates
- Dr. Veysel Kayser
-
16. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis
- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
18. Cancer vaccines
- Dr. Elias Sayour
-
19. The regulation of cell therapy
- Prof. Moutih Rafei
-
20. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
21. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
22. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
-
23. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
24. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
25. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
26. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
27. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
29. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
30. MassBank development and future
- Dr. Emma L. Schymanski
-
31. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
32. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
33. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
34. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Clinical interviews
-
35. Predicting asthma exacerbations using machine learning models
- Dr. Nestor Molfino
-
36. Fighting norovirus with a pill: new vaccine shows strong immune response- Dr. Becca Flitter
-
38. PANDAS: a potential link between group A streptococcal infections and neurological disorders
- Prof. P. Patrick Cleary
-
40. Artificial intelligence in guiding cancer treatment decisions
- Prof. Eytan Ruppin
-
41. Characterizing barriers to care in migraine
- Prof. Dawn C. Buse
-
42. Monkeypox: etiopathogenesis, prevention, and treatments
- Dr. Dennis Hruby
-
44. Kidney xenotransplantation
- Dr. Douglas J. Anderson
-
45. CAR-T and TCR-T cellular immunotherapies in oncology
- Prof. Sebastian Kobold
-
46. MAPS: the business of medical affairs
- Dr. Danie du Plessis
-
47. Hypertrophic cardiomyopathy: therapies and treatments
- Prof. Srihari Naidu
-
48. Combating the HIV epidemic
- Prof. William Blattner
-
49. Epigenetic pharmaceuticals used in the clinic
- Dr. Thomas Paul
-
50. Precision cancer medicine: development and future
- Prof. Maurie Markman
-
51. Pediatric cancer testing
- Prof. Joshua Schiffman
-
52. Opposition to vaccination: a transatlantic discussion
- Prof. Jonathan Temte
-
53. Elective caesarean sections from an evolutionary perspective
- Prof. Wenda Trevathan
-
54. Antiphospholipid syndrome and Lupus
- Prof. Graham Hughes
-
55. Prescribing medications to children - a GP’s view
- Dr. Amanda Simmons
- Annual Interviews
-
56. Antigen-specific immunotherapy for autoimmune diseases (ASIT)
- Prof. David Cameron Wraith
-
57. Recent key advancements on mechanotransduction in cardiovascular health
- Prof. Martin A. Schwartz
-
58. Recent key advancements in diabetes research
- Prof. Peter Arvan
-
59. Recent developments in pharmacovigilance
- Prof. Saad Shakir
-
60. Recent research in vaccine development
- Prof. Adam Cunningham
-
61. Recent key advancements in research on rare diseases
- Prof. Hugo J. Bellen
-
62. Recent key advancements in research on RNA-based therapies
- Prof. John P. Cooke
-
63. Recent key advancements in research on mental health disorders- Prof. Phillip D. Harvey
Topics Covered
- Alzheimer’s disease
- Neuropathology
- Molecular basis of AD
- Integrated multimodal cell atlas
Biography
Dr. Michael J. Hawrylycz is a Senior Investigator in Informatics and Data Science at the Allen Institute for Brain Science in Seattle, USA. He earned his Ph.D. in Applied Mathematics from Massachusetts Institute of Technology and previously worked in computational biology and applied mathematics. At the Allen Institute, he leads data integration and analysis efforts for large-scale brain atlasing projects such as the Allen Brain Atlas and BrainSpan, advancing understanding of brain organisation and gene expression.
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Hawrylycz, M. (2025, December 31). Integrated multimodal cell atlas of Alzheimer’s disease [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved January 2, 2026, from https://doi.org/10.69645/TYXK1457.Export Citation (RIS)
Publication History
- Published on December 31, 2025
Financial Disclosures
- Dr. Michael Hawrylycz has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Neurology
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: We're joined today
by Professor Michael Hawrylycz
from the Allen
Institute to discuss
his recent publication
in Nature Neuroscience
presenting an integrated
multimodal cell atlas
of Alzheimer's disease.
Professor Hawrylycz, thank you
very much for coming today.
Dr. Hawrylycz: Thank you.
I'm very happy to be here
as part of HSTalks.
Interviewer: To
start off, could you
start with a bit
of background on
what led your group to undertake
a multimodal approach for
studying Alzheimer's,
and what are the key
advantages of this approach
over previous research methods?
Dr. Hawrylycz: As we
know, Alzheimer's disease
is the most common cause of
dementia in older adults,
and it is a disease for which
progress has been limited
and treatments have been
somewhat ineffective.
Scientists now realize that
we really need to understand
the molecular basis of
the disease better.
Exactly how the associated
proteins accumulate.
What are the mechanisms
driving AD progression?
And what are vulnerable
cell populations
that are affected in the
course of the disease?
Several groups are now actually
pursuing this approach
by using single-cell
technologies
to explore vulnerabilities
of cell types.
What we did was essentially,
we had access to a
very strong team of
neuropathologists as well
as molecular scientists,
and we were able to
combine, essentially,
a deep profiling using
both neuropathology
classical approaches
to understanding
protein accumulations
and also the molecular basis
and alterations or what
goes wrong in the disease.